Effectiveness of a unique dihydropyridine (BAYTG 1000) for prevention of laminitis in horses.

This research study investigates the effectiveness of a specific dihydropyridine drug (BAYTG 1000) in preventing laminitis, a painful and serious disease in horses. The study concludes that BAYTG 1000 does not necessarily reduce the incidence of lameness, a symptom of laminitis, but it lessens the severity of lameness and improves the horse’s overall clinical condition 72 hours after lameness began. This suggests the drug has potential for treating laminitis.

Research Methodology

• A total of 16 normal adult horses were part of this study, arranged in eight pairs for a controlled, double-blind trial. Each pair of horses, matched for age and sex, was randomly assigned to either a treatment or control group.
• To induce laminitis, a condition characterized by lameness and inflammation of the soft tissue in the hoof, all horses were subjected to a carbohydrate overload.
• The horses in the treatment group were given BAYTG 1000 orally at a dosage of 30 mg/kg once every 24 hours for three days. Hoof wall surface temperature (HWST) and levels of lameness were regularly recorded at 4-hour intervals.
• The data was analyzed using an ANOVA test for repeated measures and Mann-Whitney procedures to evaluate lameness 8 hours after onset and clinical status 72 hours after onset of lameness.

Research Findings

• After analysis, the research found that while BAYTG 1000 did not reduce the incidence of lameness, it did noticeably mitigate prodromal hypothermia, a reducing of normal body temperature that can precede more severe symptoms.
• The drug also lessened the severity of lameness 8 hours after its onset and improved the overall health status of horses 72 hours after they began showing lameness.
• The study concluded that BAYTG 1000 can play a protective role in preventing laminitis, as it reduced the severity of induced lameness and helped enhance the overall recovery of the horses. It is surmised that the drug affects mechanisms that are secondary but important to the primary causes of laminitis.

Implications of the Study

• These results suggest that drugs capable of altering rheologic activity and enhancing digital perfusion, like BAYTG 1000, may benefit the prevention and management of laminitis in horses.
• The study adds valuable insight into future research and treatment strategies for laminitis in horses, emphasizing the potential value of drugs that can not only act on primary factors but also secondary mechanisms behind the disease.